Semaglutide Injection: How the Medication Is Administered

Published May 25, 2026Updated May 27, 2026Last reviewed May 25, 2026

For the broader cluster context, see the semaglutide dosing and protocol hub.

Author: HealthRX Editorial Team Medically reviewed by: Dr. Mark Halpern, MD (Internal Medicine, Obesity Medicine) Last clinical review: May 2026

Compounded semaglutide is not FDA-approved. This article is patient education and does not replace consultation with a licensed clinician.

Rachel, a 44-year-old project manager in Charlotte, spent twenty minutes staring at her first vial of compounded semaglutide before she could bring herself to uncap the syringe. "I watched four YouTube videos, read two pamphlets, and I still almost called my sister to come do it for me," she told her prescribing clinician at her four-week follow-up. Her injection took about six seconds. She barely felt it. This is nearly universal: the anxiety around the first semaglutide injection is wildly disproportionate to the actual experience.

But the injection itself is the easy part. What actually matters, and what most online content glosses over, is how the dosing schedule behind that injection determines whether the medication works well, works badly, or becomes intolerable. The phrase "semaglutide injection" gets tossed around in ads like it's self-explanatory. It isn't.

This guide sits inside the broader Compounded Semaglutide Dosing and Protocols cluster, which is part of the compounded semaglutide pillar guide.

The Titration Schedule That Governs Everything

The five-step titration from the STEP-1 trial is the blueprint for essentially every semaglutide protocol in clinical practice. It goes like this: 0.25 mg weekly for weeks one through four, then 0.5 mg for weeks five through eight, 1.0 mg for weeks nine through twelve, 1.7 mg for weeks thirteen through sixteen, and 2.4 mg from week seventeen onward as maintenance.

This schedule isn't arbitrary. The slow-gastric-emptying effect of GLP-1 agonism needs time to settle. Think of it like altitude acclimatization. You don't fly into Cusco and immediately hike to 16,000 feet. You stay at 11,000 for a few days. Your body adjusts. Same principle here, applied to your gut. Patients who skip steps reliably report worse nausea, worse vomiting, worse everything compared to patients who follow the ramp.

For Ozempic (the diabetes-indicated version), the escalation is shorter and tops out lower: 0.25 mg for four weeks, then 0.5 mg, then 1.0 mg, with 2.0 mg available for glycemic control. Ozempic is not labeled for chronic weight management. The pharmacy supply situation in 2026 is more stable than the chaos of 2023 and 2024, but availability still shifts.

Compounded semaglutide follows the same molecular logic. Compounding pharmacies prepare it for individual patients under a clinician prescription, and the titration is determined by the prescribing clinician. Doses are typically measured in milligrams rather than the pre-filled pen units of branded products. Compounded semaglutide is not FDA-approved.

How the Injection Actually Works

Semaglutide is subcutaneous, meaning it goes into the fatty layer just under the skin. Not into muscle. Not into a vein. The most common sites: the abdomen (at least two inches from the navel), the upper outer thigh, and the back of the upper arm. The needle gauge is small. The whole thing is quick.

A few things that matter more than people realize:

Temperature. Pull the medication out of the fridge fifteen to twenty minutes before you inject. Cold medication stings more. This is one of those simple variables that can make the difference between "barely noticed it" and "that was unpleasant."

Rotation. Use a different spot each week. Same general area is fine (abdomen one week, abdomen the next), but don't hit the exact same patch. Repeated injections in one location can cause local skin reactions.

Consistency. Pick a day. Pick a time. Stick with it. This isn't just about adherence, though that matters too. A consistent schedule makes it much easier to detect tolerability patterns. If you inject every Tuesday evening and start feeling queasy on Wednesdays, that's data. If you inject whenever you remember, you're flying blind.

Disposal. No needle reuse. Sharps go in an approved sharps container, period. Programs that prescribe compounded semaglutide via vial-and-syringe typically include supplies as part of the shipment.

Don't massage the injection site afterward. Just leave it alone.

When Dose Adjustments Enter the Picture

Three scenarios commonly trigger a conversation about adjusting the dose.

The first is GI symptoms that refuse to settle. Some nausea during titration is expected. Nausea that persists beyond a week after a dose change, or that's severe enough to affect daily functioning, is a signal to pause or step back.

The second is weight loss that's happening too fast. This sounds like a good problem until it isn't. A clinician will generally flag anything above 1.5 to 2 percent of body weight per week as unsustainable, because rapid loss at that rate brings its own risks (muscle loss, gallstones, nutritional deficiency).

The third is a plateau after months at maintenance. Here's the thing: the answer isn't always "go higher." Sometimes a stalled response at 2.4 mg calls for a different intervention entirely, whether that's a structured lifestyle change, a combination approach, or a reassessment of goals.

Where in the titration a patient sits changes the clinical calculus completely. A patient at week six with mild nausea on 0.5 mg is in a fundamentally different position than a patient at week sixteen who has tolerated 1.7 mg without difficulty. Same molecule, same question, different answer.

What the Trial Data Actually Shows

The dosing framework informing this article comes from the major semaglutide clinical trials, and it's worth being specific about what each one contributed.

STEP-1 tested 2.4 mg weekly semaglutide against placebo over 68 weeks and reported mean weight loss of 14.9 percent from baseline in the active arm. That's the headline number. It's an average, not a guarantee. Individual responses ranged widely.

STEP-3 added a structured lifestyle intervention (intensive behavioral therapy plus an initial low-calorie diet) to the same drug protocol and produced higher mean weight loss. The implication is clear: the medication alone is not the whole story.

STEP-4 is the one that should get more attention than it does. After 20 weeks of active treatment, patients were randomized to either continue semaglutide or switch to placebo. Over the next 48 weeks, the placebo group regained a significant portion of their lost weight. The chronic biology of weight regulation reasserts itself without pharmacologic support, the same way blood pressure trends upward again when you stop an antihypertensive. This is not a moral failing. It's physiology.

SUSTAIN-6 and LEADER anchor the cardiovascular safety profile for the GLP-1 class. SELECT, completed in 2023, went further: it reported a 20 percent relative reduction in major adverse cardiovascular events with semaglutide 2.4 mg in patients who had established cardiovascular disease along with overweight or obesity but not diabetes.

Four Misconceptions Worth Correcting

"Compounded semaglutide is basically the same as the branded version." Same active ingredient, yes. Same regulatory status, no. Compounding pharmacies operate under a different framework with different oversight. Compounded semaglutide is not FDA-approved, and equating it with Wegovy or Ozempic in terms of regulatory standing is inaccurate.

"If the side effects are worse, it must be working better." Trial data from STEP-1 and STEP-3 do not support this. Patients with mild GI symptoms and patients with more pronounced GI symptoms both achieved meaningful weight loss. Suffering through severe nausea is not a sign of superior response.

"The medication does all the work." STEP-3 vs. STEP-1 makes the case clearly. Semaglutide plus a structured lifestyle intervention beat semaglutide alone. This shouldn't be surprising, but it's worth repeating because every calorie consumed carries more nutritional weight when total intake is reduced. When you're eating 1,400 calories instead of 2,200, the composition of those calories matters a lot more.

"If I stop, I'll just go back to where I started." Not exactly, but the direction is correct. STEP-4 documented partial (not complete) regain over 48 weeks after discontinuation. The practical takeaway: semaglutide treats a chronic condition, and chronic conditions typically require ongoing management.

The Clinician Relationship Is the Variable That Matters Most

My genuinely opinionated take: the quality of the clinical relationship matters more than the brand of the medication or the name on the pharmacy label. A program that supports honest clinical conversation, responds to side effects with appropriate dose adjustments, and provides clear follow-up between refills will produce better outcomes than a program with slick marketing and a prescriber who rubber-stamps refills every four weeks without checking in.

The active ingredient in compounded preparations is the same as in Wegovy and Ozempic, so the molecular evidence base applies. But the regulatory status, oversight, and supply chain for compounded preparations are distinct from branded products. Individual response varies. The trial means describe averages, not individuals.

Ask questions. Report symptoms. Expect your clinician to adjust. If that's not happening, the problem isn't the injection.

Adjacent Reading

Where This Fits

This article is part of the Compounded Semaglutide Dosing and Protocols cluster. For a broader treatment of the molecule, the regulatory pathway, the 503A and 503B compounding framework, and the clinical evidence base, the compounded semaglutide pillar guide is the primary reference on this site.

Frequently Asked Questions

What dose of compounded semaglutide is considered standard?

There isn't a single "standard" dose. Compounded semaglutide protocols are written by the prescribing clinician and informed by the Wegovy escalation schedule used in STEP-1. The typical reference pattern is 0.25 mg weekly for four weeks, then 0.5 mg, 1.0 mg, 1.7 mg, and 2.4 mg, with the rate of titration adjusted to tolerability. Compounded preparations are not FDA-approved and dosing is not standardized across pharmacies.

How does titration affect tolerability?

Slow titration is the single largest determinant of gastrointestinal tolerability in published semaglutide trials. The STEP-1 protocol used four-week steps specifically to allow gastric emptying changes to adapt gradually. Skipping steps or accelerating the schedule is the most reliable way to end up miserable.

Can a clinician hold a dose without restarting titration?

Yes. Holding a current dose for an additional cycle to allow side effects to settle is a common clinical adjustment and does not require restarting the full titration schedule. That said, a multi-week gap in treatment may warrant stepping down before resuming the climb.

Where should I inject semaglutide?

The three recommended sites are the abdomen (at least two inches from the navel), the upper outer thigh, and the back of the upper arm. Rotate sites weekly to minimize local skin reactions.

Does the injection hurt?

Most patients report minimal discomfort. Letting the medication reach room temperature before injection reduces stinging. The needle gauge is small, and the injection itself takes only a few seconds.

How should I store compounded semaglutide?

Refrigerate the medication unless the compounding pharmacy specifically permits room-temperature storage for a defined window. After drawing a dose, return the vial to the fridge promptly.

Is compounded semaglutide the same as Wegovy or Ozempic?

The active ingredient is the same molecule. The regulatory status is not. Compounded semaglutide is prepared by a licensed compounding pharmacy under a clinician prescription and is not FDA-approved. The branded products have undergone full FDA review and approval processes.

Compliance and Authorship

This article references the STEP-1, STEP-3, STEP-4, SUSTAIN, SELECT, and LEADER clinical trial programs where appropriate. It is intended as patient education and does not replace consultation with a licensed clinician.